Nasdaq Marketscompaniescorporate event
AbbVie Reports Positive Phase 3 Results For Etentamig In Multiple Myeloma (opens at Nasdaq Markets in a new tab)
AbbVie announced positive topline results from the Phase 3 CERVINO trial of etentamig in relapsed/refractory multiple myeloma. The data could support regulatory submissions.
